Properties (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:activeDuring |
rofecoxib
|
| gptkbp:approves |
pain relief
rheumatoid arthritis osteoarthritis acute_pain |
| gptkbp:associatedWith |
cardiovascular risks
|
| gptkbp:class |
COX-2 inhibitor
|
| gptkbp:clinicalTrials |
yes
short-term treatment menstrual pain post-operative pain long-term treatment migraine relief treatment of gout |
| gptkbp:deployedTo |
increased risk of heart attack
increased risk of stroke |
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:discontinued |
2004
|
| gptkbp:dosageForm |
50 mg
25 mg 12.5 mg |
| gptkbp:exportMarkets |
2004
|
| gptkbp:formulation |
oral tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vioxx
|
| gptkbp:internationalClassification |
allergic reactions
liver damage skin reactions kidney problems adverse reactions |
| gptkbp:lastProduced |
1999
|
| gptkbp:legalStatus |
lawsuits
settlements |
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States anti-inflammatory medication pain reliever Vioxx_brand_name |
| gptkbp:patentExpiration |
2009
|
| gptkbp:recalls |
safety concerns
|
| gptkbp:replacedBy |
other NSAIDs
|
| gptkbp:researchInterest |
ongoing
|
| gptkbp:sideEffect |
heart attack
stroke gastrointestinal issues |
| gptkbp:targets |
inflammation
pain |
| gptkbp:usedFor |
chronic pain management
|